SOUTH SAN FRANCISCO, Calif., May 15 /PRNewswire-FirstCall/ -- Exelixis, Inc. announced today that that it will hold an analyst and investor briefing in conjunction with the 43rd Annual Meeting of the American Society of Clinical Oncology (ASCO) from 6:30 p.m. to 8:00 p.m. on Saturday, June 2, 2007.
Participants: -- George Scangos, PhD, President and Chief Executive Officer -- Michael Morrissey, PhD President, Research and Development -- Gisela Schwab, MD, Senior Vice President and Chief Medical Officer -- Peter Lamb, PhD, Senior Vice President and Chief Scientific Officer Topics: -- Clinical Strategies to Exploit MET Inhibition -- Exelixis MET Inhibitor program -- Exelixis Pipeline Update
The event will be webcast and may be accessed in the Event Calendar page under Investors at www.exelixis.com.
An archived replay of this webcast will be available until 9:00 p.m. PT/12:00 a.m. ET on July 2, 2007. Access numbers for this replay are: 1-888-286-8010 (domestic) and 1-617-801-6888 (international); Replay passcode is: 20199722.
About Exelixis
Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis’ broad product pipeline includes investigational compounds in Phase II and Phase I clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Sankyo. For more information, please visit the company’s web site at www.exelixis.com.
Exelixis, Inc.
CONTACT: investors, Charles Butler, Director, Corporate Communications,+1-650-837-7277, or cbutler@exelixis.com, or media, Soleil MaxwellHarrison, Senior Manager, Corporate Communications of Exelixis, Inc.,+1-650-837-7012, or sharrison@exelixis.com, both of Exelixis, Inc.
Web site: http://www.exelixis.com//
